Kane Biotech Inc.
KNBIF
$0.03
$0.0024.38%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.61% | -80.38% | -72.63% | 141.30% | 1,344.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.61% | -80.38% | -72.63% | 141.30% | 1,344.70% |
| Cost of Revenue | -93.25% | -65.94% | -36.66% | 354.50% | 3,358.41% |
| Gross Profit | -105.31% | -100.25% | -109.52% | 2.44% | 612.46% |
| SG&A Expenses | -53.54% | -37.60% | -52.49% | -30.74% | 21.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.42% | -49.23% | -47.27% | -13.10% | 55.82% |
| Operating Income | 42.19% | 31.78% | 35.02% | 38.80% | 2.44% |
| Income Before Tax | 44.38% | 38.44% | 35.92% | 41.33% | 17.84% |
| Income Tax Expenses | 92.04% | 91.72% | -- | -- | -- |
| Earnings from Continuing Operations | 22.85% | 17.05% | 61.82% | 64.48% | 43.40% |
| Earnings from Discontinued Operations | -- | -- | -112.16% | -111.70% | 3,258.52% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.33% | -143.26% | -156.72% | -166.27% | 220.19% |
| EBIT | 42.19% | 31.78% | 35.02% | 38.80% | 2.44% |
| EBITDA | 44.32% | 33.91% | 37.71% | 40.05% | 2.12% |
| EPS Basic | -122.54% | -133.02% | -151.29% | -168.08% | 215.33% |
| Normalized Basic EPS | 61.76% | 55.19% | 47.06% | 46.39% | 23.16% |
| EPS Diluted | -142.61% | -163.35% | -179.65% | -221.25% | 169.07% |
| Normalized Diluted EPS | 60.47% | 53.74% | 45.40% | 44.92% | 25.86% |
| Average Basic Shares Outstanding | 63.08% | 62.67% | 40.26% | 7.38% | 2.97% |
| Average Diluted Shares Outstanding | 58.70% | 58.17% | 36.99% | 5.54% | 3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |